Two Ceribell AI tools for brain monitoring have cleared the FDA. A 510(k) clearance now covers the company’s Epileptiform Abnormality Detection and Artifact Reduction algorithms, which run inside its cloud-based Neurology Portal.
The first tool watches long EEG recordings for patterns that suggest seizure activity, then flags the moments neurologists should examine. The second cleans up the signal itself, stripping interference caused by patient movement, nearby equipment, and the body’s own electrical noise. That combination attacks the two biggest problems in continuous brain monitoring: too much data and too much clutter.
The algorithms draw on over a million hours of EEG recordings, according to Ceribell. The company says activation requires no downtime or installation, and the tools work alongside its point-of-care EEG system, which can begin bedside monitoring within roughly five minutes.
Neurology staffing is a persistent bottleneck in hospitals, and AI reading tools are emerging as a workaround for long recordings that overwhelm human review. Ceribell joins a growing wave of companies pairing FDA-cleared AI with bedside devices to stretch limited neurology expertise.
